Kazakhstan's Karaganda Pharmaceutical Complex to invest $90 mln in expanding drug production

ASTANA. May 15 (Interfax) - The Kazakh government has approved a project to build a pharmaceutical plant in the Karaganda region worth 42.5 billion tenge ($89.7 million at the current exchange rate), and Prime Minister Olzhas Bektenov has signed the corresponding resolution, the government's press service said.

"The total amount of private investment is 42.5 billion tenge. The project will be one of the major investment initiatives in the industry and aims to deepen the localization of pharmaceutical production as well as develop high-tech production capacities," the press service said.

An investment agreement was signed between the Kazakh Health Ministry and Karaganda Pharmaceutical Complex LLP (KPC, one of the key enterprises in the country's pharmaceutical industry).

The plant plans to produce 74 types of medicines, including innovative drugs for the treatment of oncological, autoimmune and orphan diseases. It is expected that the enterprise will also master the synthesis of active pharmaceutical ingredients and biological and biotechnological products according to world standards.

Pharmaceutical production in Kazakhstan reached 191.1 billion tenge last year, up 8.7% compared to 2024, while investment in the industry grew from $91.3 million to $142.8 million. From December 2025 to the present, seven investment agreements totaling 360 billion tenge have been concluded in the industry, aimed at producing 474 types of medicines.

Karaganda Pharmaceutical Complex LLP is part of the Almaly holding, whose founder is businessman Kairat Boranbayev, one of the richest people in Kazakhstan.

The official exchange rate on May 15 is 474.04 tenge/$1.